McKesson Corporation (MCK)
McKesson Revenue Hurt by Supply and Demand Issues for Weight-Loss Drugs
McKesson (MCK) shares tumbled Thursday, a day after the healthcare services provider warned that limited supply of GLP-1 weight-loss drugs is hurting sales.
McKesson (MCK) Q1 Earnings Beat Estimates, Revenues Up Y/Y
McKesson's (MCK) first-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
McKesson Reports Weak Sales, Joins JFrog, Fastly, Warner Bros. Discovery And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.2% on Thursday.
McKesson (MCK) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for McKesson (MCK) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
McKesson (MCK) Tops Q1 Earnings Estimates
McKesson (MCK) came out with quarterly earnings of $7.88 per share, beating the Zacks Consensus Estimate of $7.16 per share. This compares to earnings of $7.27 per share a year ago.
McKesson misses quarterly revenue as U.S. pharmaceutical segment weighs
McKesson Corp reported weaker-than-expected first-quarter revenue on Wednesday due to soft demand for branded and specialty drugs that dragged sales down in its U.S. pharmaceuticals segment.
3 Healthcare Stocks Positioned for Possible Market Outperformance
So far in 2024, healthcare stocks have run into periodic earnings challenges compared to historical first quarters. For example, quarterly earnings for healthcare stocks across the board were down 25% compared to first-quarter 2023 earnings.
Here's Why McKesson (MCK) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should You Buy, Sell or Hold McKesson (MCK) Before Q1 Earnings?
McKesson's (MCK) first-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
Unlocking Q1 Potential of McKesson (MCK): Exploring Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for McKesson (MCK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
McKesson (MCK) Advances While Market Declines: Some Information for Investors
McKesson (MCK) reachead $629.09 at the closing of the latest trading day, reflecting a +1.96% change compared to its last close.
McKesson (MCK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
